Over the past decade, with the continuous investment and support of the country, China's biopharmaceutical innovation system has been preliminarily established, and the level of drug research and development has been in line with international standards. However, China's biopharmaceutical source innovation ability needs to be improved, and the overall "big but not strong" situation of the biopharmaceutical industry still needs to be improved. To solve these problems, strengthening basic research is the key. The biopharmaceutical industry is a key core field related to people's health, national security, and overall development. Over the past decade, with the continuous investment and support of the country, China's biopharmaceutical innovation system has been preliminarily established, and the level of drug research and development has been in line with international standards. However, China's biopharmaceutical source innovation ability needs to be improved, and the overall "big but not strong" situation of the biopharmaceutical industry still needs to be improved. To solve these problems, strengthening basic research is the key. Basic research in China's biopharmaceutical field needs to be strengthened. Through pioneering scientific discoveries and disruptive technological inventions, we continuously broaden our understanding of the mechanisms of life, enrich our means and tools to respond to disease threats, and serve as the foundation and driving force for innovation in the source of biopharmaceutical technology. Since the implementation of the "Major New Drug Creation" science and technology major special project in China in 2008, the central government has invested a total of 23.3 billion yuan to provide support for 10 major diseases and over 3000 research topics, promoting China's basic research in biopharmaceuticals onto the fast track. Nowadays, China's universities and research institutions have significantly enhanced their research and development capabilities in the field of biopharmaceuticals, with a rapid increase in the number of high-quality paper patents. Significant progress has been made in the research and development of major biopharmaceutical varieties, breaking foreign monopolies in many fields such as cancer, leukemia, and the prevention and treatment of drug-resistant bacteria. In the COVID-19, China has deployed more than 80 scientific research projects in five major directions, including drug screening, vaccine research and development, detection reagents, animal models, and scientific traceability of viruses, and has achieved a series of major basic research achievements. While affirming our achievements, we need to recognize that compared to the world's leading level, China's basic research in biopharmaceuticals is still in the stage of "following and running", and there is still great room for improvement in research and development investment, support conditions, achievement transformation, talent team, and other aspects. Firstly, in terms of research and development funds, China has invested approximately 7 billion yuan annually in basic research projects supported by the Natural Science Foundation of China. The basic research funds allocated to the fields of life sciences and medicine are relatively insufficient, and government investment needs to be further coordinated and increased in efficiency. Secondly, in terms of supporting conditions, there is still a gap in the layout of major scientific and technological infrastructure in China's biopharmaceutical field compared to foreign countries, especially the relatively insufficient supply of infrastructure that integrates biotechnology with cutting-edge fields such as artificial intelligence, big data, and advanced materials. There is a risk of "bottleneck" in the high-end instruments, equipment, materials, and scientific data required for basic research in biopharmaceutical fields. Thirdly, in terms of achievement transformation, China's successful transformation into R&D pipeline assets and even new drugs on the market is relatively limited. The conversion rate of biopharmaceutical achievements has remained around 5% for a long time, and the system and capacity for basic research to transform into industries need to be further improved. fourth